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Abstract
Background: Pazopanib, a multitargeted tyrosine kinase inhibitor, is recommended as the standard treatment for
refractory soft tissue sarcoma (STS). However, there are comparatively few molecular determinants for predicting
pazopanib efficacy. Based on correlative studies regarding the predictive impact of PD-L1, we investigated the
clinical relevance of PD-L1 expression and evaluated its value for predicting pazopanib efficacy.
Methods: Tumour tissues from patients with advanced STS who went on to receive pazopanib were assessed for
PD-L1 expression. Immunohistochemistry was performed using an anti-PD-L1 antibody, and the PD-L1 tumour
proportion score (TPS) was calculated as the percentage of at least 100 viable cells with positive expression, defined
as TPS ≥ 1%.
Results: Among the 67 patients, 8 (11.9%) achieved partial response and a median progression-free survival (PFS) of
4.8 months (95% CI 3.8–5.7). PD-L1 expression in tumour cells was detected in 13 (19.4%) cases and the TPS scores
ranged from 1 to 100%, as follows: 0 (n = 54, 80.6%), 1–9% (n = 3, 4.5%), 10–49% (n = 9, 13.4%), and ≥ 50% (n = 1,
1.5%). PD-L1 positive tumours exhibited a poorer response to pazopanib treatment than the PD-L1 negative
tumours (0% vs 14.8%, P = 0.07). PD-L1-positive tumours had significantly shorter PFS than the PD-L1-negative
tumours (median PFS 2.8 vs 5.1 months, P = 0.003), and PD-L1 positivity was an independent predictor of poor
response to pazopanib treatment (HR 2.77, 95% CI; 1.45–5.56, P = 0.006).
Conclusion: We identified that PD-L1 expression can help predict the clinical outcome of patients with advanced
STS treated with pazopanib. Based on our study, stratification should be actively considered in order to identify
patients who will benefit from pazopanib or further therapeutic strategies for future clinical trials.
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Background
Soft tissue sarcomas (STSs) comprise a rare and het-
erogeneous group of tumours that originate from
mesenchymal cells and account for 1% of all adult
malignancies [1]. Although the primary treatment is
usually surgery and/or radiotherapy, up to 40% of the
patients experience tumour recurrence, and the
survival rate is poor, with a median survival overall of
12 months [2].
For patients with advanced STS, palliative chemother-
apy generally takes the form of doxorubicin- or
ifosfamide-based regimens [2, 3]. If first-line treatment
fails, trabectedine, dacarbazine and gemcitabine, and/or
docetaxel, have been approved as salvage treatments.
Pazopanib is a multitargeted tyrosine kinase inhibitor
that shows activity against vascular endothelial growth
factor, platelet-derived growth factor, fibroblast growth
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factor receptors, and c-kit. In a stratified phase II trial
for advanced STS [4], pazopanib displayed anti-cancer
activity against leiomyosarcoma and synovial sarcoma,
but not liposarcoma. In a subsequent phase III Pazopa-
nib for Metastatic Soft-Tissue Sarcoma (PALETTE) trial
designed for investigating the effect of pazopanib on
non-adipocytic STS, it was observed that pazopanib
treatment resulted in an improved progression-free sur-
vival (3 months) compared to that observed in response
to the placebo [5]. While pazopanib is currently recom-
mended as a standard treatment, patient response to this
drug is still modest and the improvement of overall sur-
vival is not significant. We hypothesise that identifying
molecular predictors to select patients who might bene-
fit from pazopanib treatment might improve the efficacy
of this drug. While previous studies have reported a
number of clinical parameters as predictors of pazopanib
efficacy, including circulating angiogenic factors and
neutrophil to lymphocyte ratios, the application of these
parameters has been limited thus far [6, 7].
Based on our understanding of the mechanisms by
which tumours evade the immune response, immune
checkpoint inhibitor-based therapies (e.g.: pembrolizu-
mab monotherapy, combinatorial therapy with nivolu-
mab and ipilimumab, a cytotoxic T-lymphocyte–
associated antigen 4 (CTLA-4) inhibitor) have been de-
veloped which show an effect on advanced STS [8, 9].
Programmed death-ligand 1 (PD-L1) is aberrantly
expressed in several subtypes of STS and has been asso-
ciated with poor prognosis and adverse features [10, 11].
Recently, a correlation between PD-L1 expression and
clinical outcome was reported in renal cell carcinoma
(RCC). Choueiri et al. showed that patients with higher
PD-L1 expression had worse overall survival when
treated with pazopanib or sunitinib [12]. However, the
predictive impact of PD-L1 in STS remains unclear, and
further research is warranted to provide more detailed
therapeutic guidance regarding the treatment of this
disease.
In this study, we investigated PD-L1 expression in STS
tissues and evaluated the clinical relevance of its expres-
sion in different STS subtypes. In addition, we also eval-
uated the correlation between the expression of PD-L1
and treatment outcomes of patients who received pazo-
panib, for facilitating the identification of a molecular
biomarker that could aid the design of effective STS
treatments.
Methods
Patient and study procedure
We retrospectively selected 91 patients who were patho-
logically diagnosed with STS, from September 2013 to
December 2019, at Yonsei Cancer Center, Yonsei Uni-
versity College of Medicine. Among these patients, 24
were excluded due to the lack of available specimens
(n = 13) or insufficient tumour content (n = 11); 67 pa-
tients were finally included in this study. To select the
most representative formalin-fixed paraffin-embedded
(FFPE) tissues for immunohistochemistry, samples were
mounted on slides, stained with haematoxylin and eosin,
and reviewed by two pathologists (SKK and HYW).
These tissue used for analysis were before pazopanib
treatment.
Clinical information, including age, sex, etiology, East-
ern Cooperative Oncology Group (ECOG) performance
status, French Federation of Cancer Centers Sarcoma
Group (FNCLCC) system score, staging and previous
treatment data, were extracted from the hospital records.
The study was reviewed and approved by the Institu-
tional Review Board of the Yonsei Cancer Center (IRB.
4–2017-1023) in accordance with the Declaration of
Helsinki and the Guidelines for Good Clinical Practice.
Immunohistochemistry and evaluation of PD-L1
expression and tumour infiltrating lymphocytes (TIL)
score
In patients treated with pazopanib in combination with
anti-PD-L1 blockade, PD-L1 expression was analysed
using an anti-PD-L1 antibody (clone SP263, Ventana).
From each block, 5 μm sections were cut and stained
using the anti-PD-L1 antibody on an automated staining
platform (Benchmark ULTRA; Ventana). An OptiView
DAB IHC Detection Kit and an OptiView Amplification
Kit (both Ventana) were used according to the manufac-
turer’s recommendations for the visualisation of PD-L1
protein. The PD-L1 tumour proportion score (TPS) was
expressed as the percentage of at least 100 viable cells
exhibiting complete or partial membrane staining and a
three-tiered system was then applied using the following
thresholds: < 1%, 1–49% and ≥ 50%. Positive expression
was defined as TPS ≥ 1%. Macrophages were used as an
internal control in order to validate the adequacy of the
PD-L1 staining.
The percentage of intratumoural and stromal tumour
infiltrating lymphocytes (TILs) was evaluated using the
criteria described and published by the International
Immuno-Oncology Biomarker Working Group [13].
Briefly, all mononuclear cells, excluding neutrophils,
were scored, and the average number of TILs in the
tumour area was assessed as a continuous variable. TIL
scores were classified into the following three groups:
negative (< 1%), low (1–9%), intermediate (10–59%), and
high (≥ 60%), by adopting the definition published by
Ogiya et al. [14]
Statistical analysis
Progression-free survival (PFS) was defined as the time
from the start of pazopanib treatment until the date of
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disease progression or death resulting from any cause.
Overall survival (OS) was measured from the start of
pazopanib treatment with advanced STS to the date of
death due to any cause. Survival difference was analysed
using the Kaplan–Meier method and was assessed using
the log-rank test. Overall response rate (ORR) was calcu-
lated as the percentage of patients experiencing a con-
firmed complete response (CR) or partial response (PR),
as per the Response Evaluation Criteria in Solid Tumors
(RECIST) 1.1 guidelines. The associations between clin-
ical features and each of the dichotomised groups were
analysed using the chi-square test or Fisher’s exact test.
All P-values were two-sided and p < 0.05 was considered
significant. Statistical analysis was conducted using SPSS
(version 21.0; SPSS, Inc., Chicago, IL) and GraphPad
Prism version 5 (Graph Pad Software Inc., San Diego,
CA, USA.
Results
Clinicopathological characteristics of sarcoma patients
FFPE primary tumour specimens from a total of 67 pa-
tients with unresectable or metastatic STS were analysed
for PD-L1 expression using immunohistochemistry.
Fifty-two cases (77.6%) were made from surgical speci-
mens and 15 (22.4%) from biopsy samples. And 58 cases
(86.6%) were from the primary tumor site and 9 (13.4%)
from metastasis sites. Twelve cases (17.9%) were tissue
samples obtained after chemotherapy, of which 7 cases
were after the first chemotherapy and 5 cases were after
the second chemotherapy or more. The most commonly
observed histologies were leiomyosarcoma (n = 18), un-
differentiated pleomorphic sarcoma (UPS; n = 13), angio-
sarcoma (n = 8), and synovial sarcoma (n = 6). The
majority of the tumours were high grade (FNCLCC
grade 2 or 3; 91.0%) and 61.2% of them arose in the ab-
domen or thorax. All patients had received at least one
previous regimen of chemotherapy, mainly doxorubicin
or gemcitabine plus docetaxel based (Table 1).
Correlation between PD-L1 expression and the TIL score
Overall, PD-L1 expression in the tumour cells was de-
tected in 13 (19.4%) of the 67 patients, with TPS scores
ranging from 1 to 100% positive staining in the following
manner: 0 (n = 54, 80.6%), 1–9% (n = 3, 4.5%), 10–49%
(n = 9, 13.4%), and ≥ 50% (n = 1, 1.5%) positive staining.
Representative images are provided in Fig. 1. PD-L1-
positive (+) cases were common in UPS, angiosarcoma,
malignant peripheral nerve sheath tumour (MPNST),
and leiomyosarcoma but none of the synovial sarcoma
tumours exhibited PD-L1 expression. PD-L1 (+) patients
tended to present a higher grade and head/neck primary
tumour.
The inflammatory response, as represented by the
presence of TILs, was simultaneously evaluated in the
following manner: negative (n = 39, 58.2%), low TIL (n =
16, 23.9%), intermediate TIL (n = 11, 16.4%), and high
TIL (n = 1, 1.5%) sarcoma. There was a possible correl-
ation between PD-L1-positive staining and TILs, and the
percentage of TILs showed a tendency to increase ac-
cording to the degree of PD-L1-positive staining (P =
0.09, Table 2). No significant difference was detected
when the TIL score was evaluated with respect to other
clinical characteristics (age, sex, ECOG performance,
histologic subtype, and primary tumour site).
Correlation between PD-L1 expression with pazopanib
efficacy
Of the 67 patients evaluated, 8 achieved a PR, 36 had
stable disease, and 23 exhibited progressive disease phe-
notypes, resulting in an ORR of 11.9% (Fig. 2a). Re-
sponses were first detected at a median of 2.3 months
(range 1.8–8.2) after treatment initiation and lasted for a
median of 6.5 months (range 2.1–19.6). Responder who
showed PR had higher PD-L1 negativity than non-
responder who showed SD and progression disease (PD)
(100% versus 83.3% versus 69.6%, Fig. 2b). The ORRs of
the different histological subtypes were as follows; 2 PRs
(11.1%) among 18 leiomyosarcomas, 1 (7.7%) in 13 UPS,
1 (12.5%) of 8 angiosarcomas, and 1 (33.3%) of 3 epithe-
lioid sarcomas. In synovial sarcoma, 3 PRs (50%) were
detected, of which 2 were biphasic and 1 was monopha-
sic (Fig. 2c). Brief case descriptions of PD-L1 (+) expres-
sion are supplied in Supplementary Table 1.
Fifty-nine patients (88.1%) exhibited progressive events
and the median PFS was 4.8 months (95% CI 3.8–5.7). Pa-
tients with PD-L1 (+) expression had significantly shorter
PFS than PD-L1 (−) patients (median PFS 2.8 vs 5.1
months, P = 0.003, Fig. 3a). This trend was consistent for
second-line–treated patients (Fig. 3b, median 2.8 vs 5.0
months, P < 0.001). The median OS was 10.1months (95%
CI 5.42–14.78), and PD-L1-negative patients had a slightly
better OS than PD-L1-positive patients, although this was
not significant (12.6 vs 7.9 months, P = 0.11, Fig. 3c).
In multivariate Cox regression analyses, only PD-L1
(+) expression was identified to be an independent factor
for determining poor PFS upon pazopanib treatment
(HR 2.77, 95% CI; 1.45–5.56, P = 0.006, Table 3). Further
analyses using TILs showed that a combination of PD-
L1 (+) and higher TIL expression counts correlated with
shorter PFS, and that patients positive for both PD-L1
and TILs had the shortest PFS [5.1 vs 4.3 vs 2.7 months
for both PD-L1 (−) and TIL (−) vs PD-L1 (+) or TIL (+)
vs both PD-L1 (+) and TIL (+), P = 0.035, Fig. 3d].
Discussion
Using a standardised assay, in the current study we re-
port the expression of PD-L1 in pre-treated STS tumour
tissues. Furthermore, our study unravels the value of
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Table 1 Patient characteristics.
Variables Total PD-L1 (−) PD-L1 (+) P value
54 (80.6%) 13 (19.4%)
Age (Median) 48 51 (38–73) 45 (22–72)
Sex 0.82
Male 38 31 (81.6%) 7 (18.4%)
Female 29 23 (79.3%) 6 (20.7%)
ECOG 0.99
0 3 3 (100%) 0 (0.0%)
1 36 28 (77.8%) 8 (22.2%)
2 26 21 (80.8%) 5 (19.2%)
Not available 2 2 (100%) 0 (0.0%)
Histologic variant 0.22
Leiomyosarcoma 18 15 (83.3%) 3 (16.7%)
Undifferentiated pleomorphic sarcoma 13 9 (69.2%) 4 (30.8%)
Angiosarcoma 8 5 (62.5%) 3 (37.5%)
Synovial sarcoma 6 6 (100%) 0 (0.0%)
Myofibroblastic sarcoma 6 5 (83.3%) 1 (16.7%)
MPNST 5 3 (60%) 2 (40%)
Etc* 11 11 (100%) 0 (0.0%)
Primary site 0.23
Abdomen/pelvis 23 20 (87.0%) 3 (13.0%)
Extremity 22 19 (86.4%) 3 (13.6%)
Thorax 18 13 (72.2%) 5 (27.8%)
Head/neck 4 2 (50%) 2 (50%)
FNCLCC grade 0.36
I 6 6 (100%) 0 (0.0%)
II 33 27 (81.8%) 6 (19.2%)
III 28 21 (75%) 7 (25%)
Number of previous chemotherapy 0.83
1 48 38 (79.2%) 10 (20.8%)
2 18 15 (83.3%) 3 (16.7%)
3 1 1 (100%) 0 (0.0%)
Type of previous chemotherapy received NA
Doxorubicin monotherapy 9 7 (77.8%) 2 (22.2%)
Ifosfamide monotherapy 3 2 (66.7%) 1 (33.3%)
Paclitaxel 4 3 (75.0%) 1 (25.0%)
Doxorubicin combination 33 28 (84.8%) 5 (15.2%)
Ifosfamide combination 4 3 (66.7%) 1 (33.3%)
Cyclophosphamide based 14 11 (78.6%) 3 (21.4%)
Gemcitabine/docetaxel 14 12 (85.7%) 2 (14.3%)
* 8th edition of the American Joint Committee on Cancer guideline of tumor, node, and metastasis (TNM) classification
*Etc: ASPS (alveolar soft part sarcoma, n = 3), epithelioid sarcoma (n = 3), DSRCT (desmoplastic small round cell tumors, n = 1), osteosarcoma (n = 1), liposarcoma
(n = 1), rhabdomyosarcoma (n = 1), and PECOMA (perivascular epithelioid cell tumors, n = 1)
Abbreviation: Eastern Cooperative Oncology Group (ECOG), malignant peripheral nerve sheath tumor (MPNST), Fédération Nationale des Centres de Lutte Contre
le Cancer (FNCLCC)
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Fig. 1 Immunohistochemistry for PD-L1 expression in STS. Representative images of PD-L1-negative (a, TPS 0%, × 100) and -positive cases (b, TPS
40%, × 100) (c, TPS 100%, × 100). Abbreviation: Programmed death-ligand 1(PD-L1), soft tissue sarcoma (STS), tumour proportion score (TPS)
Table 2 Correlation between PD-L1 expression and TIL
PD-L1 (%) Total
0 1–9 10–49 ≥50 P = 0.09
TIL Negative (0) 34 (62.9%) 1 (33.3%) 4 (44.4%) 0 39 (58.2%)
Low (1–9) 13 (24.1%) 2 (66.7%) 1 (11.1%) 0 16 (23.9%)
Intermediate (10–59) 6 (11.1%) 0 4 (44.4%) 1 (100%) 11 (16.4%)
High (≥60) 1 (1.9%) 0 0 0 1 (1.5%)
54 (80.6%) 3 (4.5%) 9 (13.4%) 1 (1.5%)
Abbreviation: Programmed death-ligand 1(PD-L1), tumour infiltrating lymphocytes (TILs)
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PD-L1 for predicting pazopanib efficacy. To our know-
ledge, this is the first study to evaluate the role of PD-L1
expression in pazopanib response in STS.
Pazopanib, an inhibitor of angiogenesis and tumour
cell proliferation, has been recognized as a salvage treat-
ment for STS [5]. The approval of this drug was based
on the results of the randomised phase III PALETTE
trial, which showed that pazopanib improved PFS in
patients with previously treated STS compared to pla-
cebo treatment. However, despite the prolonged PFS, no
significant difference in OS was observed, and our un-
derstanding of the factors mediating pazopanib sensitiv-
ity and resistance is still poor. There is an urgent need
for the identification of predictive biomarkers which can
be used to select subgroups of patients who will benefit
from pazopanib treatment. In the PALETTE trial, it was
Fig. 2 Maximum response to pazopanib in patients with STS. (a) The waterfall plot represents percentage of maximum tumour reduction in
response to treatment, assessed according to RECIST 1.1 criteria. * indicates newly developed lesions per RECIST 1.1. (b) Prevalence of PD-L1
expression in responders (PR) and non-responders (SD, PD), assessed according to RECIST 1.1 criteria. (c) Maximum tumour reduction according
to histological subtypes and PD-L1 status. PD-L1 TPS score (≥1%) has been plotted on the X-axis and PD-L1 positive marked in light color bars.
Indicates rhabdomyosarcoma and ¥ indicates ASPS (Alveolar soft part sarcoma). Abbreviation: Soft tissue sarcoma (STS), Response Evaluation Criteria
in Solid Tumors (RECIST) 1.1, Programmed death-ligand 1(PD-L1), tumour proportion score (TPS), PR (partial response), SD (stable disease), PD
(progression disease). *This figure was generated with Microsoft Excel
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Fig. 3 Survival analyses based on PD-L1 expression. Kaplan–Meier survival curves for PFS for all patients (a) and those with second-line treatment
(b). Kaplan–Meier survival curves for OS (c). PFS difference in response to the combined expression of PD-L1 and TILs (d). Abbreviation:
Programmed death-ligand 1(PD-L1), progression-free survival (PFS), overall survival (OS), tumour infiltrating lymphocytes (TILs). *This figure was
generated with GraphPad Prism version 5 (Graph Pad Software Inc., San Diego, CA, USA)
Table 3 Prognostic Factors for Progression-free survival
Hazard Ratio (95% CI) P value
Performance (0 vs 1) 0.74 (0.39–1.44) 0.38
Number of previous chemotherapy (1 vs 2–3) 0.67 (0.29–1.57) 0.36
Sex (female vs male) 1.27 (0.65–2.49) 0.49
Age (≤48 years vs > 48 years) 1.69 (0.86–3.30) 0.12
ECOG (0–1 vs 2) 0.74 (0.39–1.44) 0.38
Grade (I vs II-III) 1.22 (0.43–3.45) 0.77
Histologic subtype
(leiomyosarcoma and synovial sarcoma
vs other subtypes*)
1.17 (0.49–2.06) 0.95
Locoregional disease (yes vs no) 1.10 (0.60–2.03) 0.75
Liver metastases (yes vs no) 0.75 (0.22–2.58) 0.65
PD-L1 expression (positive vs negative) 2.77 (1.45–5.56) 0.006
TIL (high vs low) 1.41 (0.83–2.37) 0.197
*other subtypes: undifferentiated pleomorphic sarcoma, angiosarcoma, myofibroblastic sarcoma, MPNST (malignant peripheral nerve sheath tumor), ASPS
(Alveolar soft part sarcoma), epithelioid sarcoma, DSRCT, osteosarcoma, liposarcoma, rhabdomyosarcoma, and PECOMA
Abbreviation: Eastern Cooperative Oncology Group (ECOG), tumour infiltrating lymphocytes (TILs)
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noted that patients with leiomyosarcoma and synovial
sarcoma exhibited better PFS upon pazopanib; however,
a significant interaction with histological subtypes was
not identified in predictive analysis. Other biological
markers include post-treatment neutrophil-lymphocyte
ratio, which was also suggested to be a robust predictive
factor for pazopanib efficacy [7]. However, haemato-
logical parameters (such as neutrophil and lymphocyte
counts) are unreliable because they can be easily influ-
enced by other inflammatory conditions. Although a
number of potential biomarkers have also been investi-
gated, none of these are available as patient selection
strategies for use in clinical practice.
Immune checkpoint inhibitors that block PD-1 and
PD-L1 have exhibited remarkable efficacy with respect
to the treatment of refractory solid tumours including
melanoma and RCC, and substantial attention has been
paid to assessing PD-L1 expression in STS. PD-L1 ex-
pression has been studied in various STS subtypes [10],
and a recent meta-analysis also reported a role for PD-
L1 expression in the poor prognosis of bone and STS
[15]. Interestingly, immunotherapy resulted in the gener-
ation of a response in certain sarcoma subtypes, mainly
UPS, liposarcoma, and angiosarcoma [8, 9]. The Cancer
Genome Atlas (TCGA) analysis have described the fol-
lowing immune classification based on the composition
of the tumor microenvironment in STS: immune-low,
immune-high, and vascularized group. In this study,
immune-high group (mainly UPS and liposarcoma) ex-
hibited high expression of PD1, PDL2, and CTLA-4 [16].
Consistent with previous studies, we show that PD-L1
(+) was commonly observed in UPS, angiosarcoma, and
leiomyosarcoma, and that PD-L1 (+) staining independ-
ently correlated with poor efficacy of pazopanib treat-
ment. Furthermore, none of the synovial sarcoma
tumours exhibited PD-L1 expression and this subtype
exhibited a higher response to pazopanib treatment.
Similarly, the synovial sarcoma subtype also showed
favourable responses to pazopanib in the PALETTE trial
[5]. Therefore, we propose that PD-L1 expression is as-
sociated with pazopanib resistance and that this hypoth-
esis is worth further testing as a therapeutic strategy in
future clinical trials.
A recent report described a correlation between PD-L1
expression on the tumour and the efficacy of pazopanib or
sunitinib treatment in metastatic RCC. Patients whose tu-
mours were TIL-positive and/or displayed high PD-L1 ex-
pression had poor survival outcomes in response to
vascular endothelial growth factor (VEGF)-targeted agents
[12]. A preclinical study showed that anti-PD-L1 therapy
enhances tumour sensitivity to antiangiogenic therapy by
inducing the development of endothelial venules that fa-
cilitate cytotoxic T cell activity and tumour lysis [17].
Therefore, on the basis that the VEGF receptor (VEGFR)
plays a central role in immunosuppression, a strategy of
combination treatments has been widely studied in RCC
[18, 19]. Similarly, the combination of a VEGF inhibitor,
axitinib, with pembrolizumab was shown to have promis-
ing efficacy in advanced sarcomas, particularly in patients
with advanced soft-part sarcoma [20]. Taken together, the
combination of pazopanib and PD-L1 blockade may be a
promising future therapeutic option for STS, and the final
results of an ongoing trial (A Study of Pazopanib and Dur-
valumab for Metastatic Soft Tissue Sarcoma;
ClinicalTrials.gov Identifier: NCT03798106) may help to
confirm this premise.
To clarify the exact characteristics and prognostic role
of PD-L1 expression, we carefully assessed a large cohort
of patients with STS who were treated with pazopanib.
Furthermore, from a practical perspective, three different
PD-L1 antibodies (22C3, 28–8, and SP263) showed com-
parable analytical performance with respect to assessing
PD-L1 expression [21]. Therefore, we used a companion
diagnostic marker for approved anti-PD-L1 antibodies,
SP263 PD-L1, in accordance with a standard protocol
(instrument platform, staining procedure, and scoring
methods) to provide a practical guideline. However, be-
cause of the retrospective nature of this study, future
studies should evaluate a larger, prospective cohort to
address the question of whether PD-L1 expression can
serve as a clinical prognostic marker for STS.
Conclusions
Our study described a predictive role for PD-L1 expres-
sion in assessing the clinical outcomes for patients with
advanced STS treated with pazopanib. This study pro-
vides important information that can guide treatment
choices to better tailor the efficacy of pazopanib, thereby
leading to new therapeutic strategies for sarcoma.
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